Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD) [Phase 1]

View source ↗

Summary

A Phase 1 study assessing the pharmacokinetics, safety, and tolerability of ABBV-932 in healthy volunteers and in individuals with generalized anxiety disorder …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Generalized Anxiety Disorder

Drugs mentioned

• ABBV-932

Snippet

Sponsor: AbbVie | Conditions: Healthy Volunteers, Generalized Anxiety Disorder (GAD) | Phase 1 | Status: COMPLETED